Functional, non-clonal IgMa-restricted B cell receptor interactions with the HIV-1 envelope gp41 membrane proximal external region

PLoS ONE

Volumn 4, Issue 10, 2009, Pages

  Verkoczy, Laurent ^a   Moody, M Anthony ^a   Holl, T Matt ^a   Bouton Verville, Hilary ^a   Scearce, Richard M ^a   Hutchinson, Jennifer ^a   Alam, S Munir ^a   Kelsoe, Garnett ^a   Haynes, Barton F ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

B LYMPHOCYTE RECEPTOR; EPITOPE; GLYCOPROTEIN GP 41; IMMUNOGLOBULIN FC FRAGMENT; IMMUNOGLOBULIN HEAVY CHAIN; IMMUNOGLOBULIN M; MONOCLONAL ANTIBODY 2F5; MONOCLONAL ANTIBODY 4E10; TETRAMER; B CELL ACTIVATING FACTOR RECEPTOR; CD79 ANTIGEN;

ANIMAL CELL; ANIMAL TISSUE; ANTIBODY PRODUCTION; ARTICLE; B LYMPHOCYTE; B LYMPHOCYTE ACTIVATION; BAGG ALBINO MOUSE; C57BL 6 MOUSE; CONGENIC STRAIN; CONTROLLED STUDY; EPITOPE MAPPING; FEMALE; GENE LOCUS; IMMUNOGLOBULIN PRODUCTION; IN VITRO STUDY; MOUSE; NONHUMAN; PROTEIN PROTEIN INTERACTION; SIGNAL TRANSDUCTION; STRAIN DIFFERENCE; ANIMAL; C57BL MOUSE; CELL MEMBRANE; CHEMISTRY; HUMAN IMMUNODEFICIENCY VIRUS 1; LYMPHOCYTE ACTIVATION; METABOLISM; PROTEIN BINDING; SPLEEN; VIROLOGY;

HUMAN IMMUNODEFICIENCY VIRUS 1; MUS;

ANIMALS; ANTIGENS, CD79; B-CELL ACTIVATION FACTOR RECEPTOR; B-LYMPHOCYTES; CELL MEMBRANE; EPITOPES; FEMALE; HIV ENVELOPE PROTEIN GP41; HIV-1; LYMPHOCYTE ACTIVATION; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; PROTEIN BINDING; SIGNAL TRANSDUCTION; SPLEEN;

EID: 70350221801     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0007215     Document Type: Article

References (81)

1. Bures R, Gaitan A, Zhu T, Graziosi C, McGrath KM, et al. (2000) Immunization with recombinant canarypox vectors expressing membrane-anchored glycoprotein 120 followed by glycoprotein 160 boosting fails to generate antibodies that neutralize R5 primary isolates of human immunodeficiency virus type 1. AIDS Res Hum Retroviruses 16: 2019-2035.
2. D'Souza MP, Livnat D, Bradac JA, Bridges SH (1997) Evaluation of monoclonal antibodies to human immunodeficiency virus type 1 primary isolates by neutralization assays: performance criteria for selecting candidate antibodies for clinical trials. AIDS Clinical Trials Group Antibody Selection Working Group. J Infect Dis 175: 1056-1062.
3. Gao F, Weaver EA, Lu Z, Li Y, Liao HX, et al. (2005) Antigenicity and immunogenicity of a synthetic human immunodeficiency virus type 1 group m consensus envelope glycoprotein. J Virol 79: 1154-1163.
4. Nelson JD, Brunel FM, Jensen R, Crooks ET, Cardoso RM, et al. (2007) An affinity-enhanced neutralizing antibody against the membrane-proximal external region of human immunodeficiency virus type 1 gp41 recognizes an epitope between those of 2F5 and 4E10. J Virol 81: 4033-4043.
5. Kwong PD, Doyle ML, Casper DJ, Cicala C, Leavitt SA, et al. (2002) HIV-1 evades antibody-mediated neutralization through conformational masking of receptor-binding sites. Nature 420: 678-682.
6. Kwong PD, Wyatt R, Robinson J, Sweet RW, Sodroski J, et al. (1998) Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody. Nature 393: 648-659.
7. Wei X, Decker JM, Wang S, Hui H, Kappes JC, et al. (2003) Antibody neutralization and escape by HIV-1. Nature 422: 307-312.
8. Wyatt R, Kwong PD, Desjardins E, Sweet RW, Robinson J, et al. (1998) The antigenic structure of the HIV gp120 envelope glycoprotein. Nature 393: 705-711.
9. Burton DR, Desrosiers RC, Doms RW, Koff WC, Kwong PD, et al. (2004) HIV vaccine design and the neutralizing antibody problem. Nat Immunol 5: 233-236.
10. Richman DD, Wrin T, Little SJ, Petropoulos CJ (2003) Rapid evolution of the neutralizing antibody response to HIV type 1 infection. Proc Natl Acad Sci U S A 100: 4144-4149.
11. Haynes BF, Montefiori DC (2006) Aiming to induce broadly reactive neutralizing antibody responses with HIV-1 vaccine candidates. Expert Rev Vaccines 5: 579-595.
12. Mascola JR, Lewis MG, Stiegler G, Harris D, VanCott TC, et al. (1999) Protection of Macaques against pathogenic simian/human immunodeficiency virus 89.6PD by passive transfer of neutralizing antibodies. J Virol 73: 4009-4018.
13. Mascola JR, Stiegler G, VanCott TC, Katinger H, Carpenter CB, et al. (2000) Protection of macaques against vaginal transmission of a pathogenic HIV-1/SIV chimeric virus by passive infusion of neutralizing antibodies. Nat Med 6: 207-210.
14. Barbato G, Baianchi P, Inagallinella P, Hurni WM, Miller DJ, et al. (2003) Structural analysis of the epitope of the anti-HIV antibody 2F5 sheds light into its mechanism of neutralization and HIV fusion. J Mol Biol 330: 1101-1115.
15. Buchacher A, Predl R, Strutzenberger K, Steinfellner W, Trkola A, et al. (1994) Generation of human monoclonal antibodies against HIV-1 proteins; electrofusion and Epstein-Barr virus transformation for peripheral blood lymphocyte immortalization. AIDS Res Hum Retroviruses 10: 359-369.
16. Cardoso RM, Zwick MB, Stanfield RL, Kunert R, Binley JM, et al. (2005) Broadly neutralizing anti-HIV antibody 4E10 recognizes a helical conformation of a highly conserved fusion-associated motif in gp41. Immunity 22: 163-173.
17. Muster T, Steindl F, Purtscher M, Trkola A, Klima A, et al. (1993) A conserved neutralizing epitope on gp41 of human immunodeficiency virus type 1. J Virol 67: 6642-6647.
18. Ofek G, Tang M, Sambor A, Katinger H, Mascola JR, et al. (2004) Structure and mechanistic analysis of the anti-human immunodeficiency virus type 1 antibody 2F5 in complex with its gp41 epitope. J Virol 78: 10724-10737.
19. Stiegler G, Kunert R, Purtscher M, Wolbank S, Voglauer R, et al. (2001) A potent cross-clade neutralizing human monoclonal antibody against a novel epitope on gp41 of human immunodeficiency virus type 1. AIDS Res Hum Retroviruses 17: 1757-1765.
20. Zwick MB, Jensen R, Church S, Wang M, Stiegler G, et al. (2005) Anti-human immunodeficiency virus type 1 (HIV-1) antibodies 2F5 and 4E10 require surprisingly few crucial residues in the membrane-proximal external region of glycoprotein gp41 to neutralize HIV-1. J Virol 79: 1252-1261.
21. Zwick MB, Labrijn AF, Wang M, Spenlehauer C, Saphire EO, et al. (2001) Broadly neutralizing antibodies targeted to the membrane-proximal external region of human immunodeficiency virus type 1 glycoprotein gp41. J Virol 75: 10892-10905.
22. Zwick MB, Wang M, Poignard P, Stiegler G, Katinger H, et al. (2001) Neutralization synergy of human immunodeficiency virus type 1 primary isolates by cocktails of broadly neutralizing antibodies. J Virol 75: 12198-12208.
23. Coeffier E, Clement JM, Cussac V, Khodaei-Boorane N, Jehanno M, et al. (2000) Antigenicity and immunogenicity of the HIV-1 gp41 epitope ELDKWA inserted into permissive sites of the MalE protein. Vaccine 19: 684-693.
24. Eckhart L, Raffelsberger W, Ferko B, Klima A, Purtscher M, et al. (1996) Immunogenic presentation of a conserved gp41 epitope of human immunodeficiency virus type 1 on recombinant surface antigen of hepatitis B virus. J Gen Virol 77 (Pt 9): 2001-2008.
25. Joyce JG, Hurni WM, Bogusky MJ, Garsky VM, Liang X, et al. (2002) Enhancement of alpha-helicity in the HIV-1 inhibitory peptide DP178 leads to an increased affinity for human monoclonal antibody 2F5 but does not elicit neutralizing responses in vitro. Implications for vaccine design. J Biol Chem 277: 45811-45820.
26. Liang X, Munshi S, Shendure J, Mark G 3rd, Davies ME, et al. (1999) Epitope insertion into variable loops of HIV-1 gp120 as a potential means to improve immunogenicity of viral envelope protein. Vaccine 17: 2862-2872.
27. Marusic C, Rizza P, Lattanzi L, Mancini C, Spada M, et al. (2001) Chimeric plant virus particles as immunogens for inducing murine and human immune responses against human immunodeficiency virus type 1. J Virol 75: 8434-8439.
28. Earl PL, Broder CC, Doms RW, Moss B (1997) Epitope map of human immunodeficiency virus type 1 gp41 derived from 47 monoclonal antibodies produced by immunization with oligomeric envelope protein. J Virol 71: 2674-2684.
29. Eckert DM, Kim PS (2001) Mechanisms of viral membrane fusion and its inhibition. Annu Rev Biochem 70: 777-810.
30. Weissenhorn W, Dessen A, Harrison SC, Skehel JJ, Wiley DC (1997) Atomic structure of the ectodomain from HIV-1 gp41. Nature 387: 426-430.
31. Alam SM, McAdams M, Boren D, Rak M, Scearce RM, et al. (2007) The role of antibody polyspecificity and lipid reactivity in binding of broadly neutralizing anti-HIV-1 envelope human monoclonal antibodies 2F5 and 4E10 to glycoprotein 41 membrane proximal envelope epitopes. J Immunol 178: 4424-4435.
32. Haynes BF, Fleming J, St Clair EW, Katinger H, Stiegler G, et al. (2005) Cardiolipin polyspecific autoreactivity in two broadly neutralizing HIV-1 antibodies. Science 308: 1906-1908.
33. Sanchez-Martinez S, Lorizate M, Katinger H, Kunert R, Nieva JL (2006) Membrane association and epitope recognition by HIV-1 neutralizing anti-gp41 2F5 and 4E10 antibodies. AIDS Res Hum Retroviruses 22: 998-1006.
34. Haynes BF, Moody MA, Verkoczy L, Kelsoe G, Alam SM (2005) Antibody polyspecificity and neutralization of HIV-1: a hypothesis. Hum Antibodies 14: 59-67.
35. Haynes BF, Alam SM (2008) HIV-1 Hides an Achilles' Heel in Virion Lipids. Immunity 28: 10-12.
36. Sun Z-Y, Oh KG, Kim M, Yu J, Brusic V, et al. (2008) HIV-1 broadly neutralizing antibody extracts its epitope from a kinked MPER segment on the viral membrane. Immunity 28: 52-63.
37. Silverman GJ, Goodyear CS (2006) Confounding B-cell defences: lessons from a staphylococcal superantigen. Nat Rev Immunol 6: 465-475.
38. He B, Qiao X, Klasse PJ, Chiu A, Chadburn A, et al. (2006) HIV-1 envelope triggers polyclonal Ig class switch recombination through a CD40-independent mechanism involving BAFF and C-type lectin receptors. J Immunol 176: 3931-3941.
39. Moody MA, Verkoczy L, Drinker MS, Gurley TC, Marshall DJ, et al. (2008) Envelope epitope tetramers for identification and isolation of HIV-1 epitope-specific B lymphocytes. Nature Biotechnology. Submitted.
40. Alam SM, Scearce RM, Parks RJ, Plonk K, Plonk SG, et al. (2008) Human immunodeficiency virus type 1 gp41 antibodies that mask membrane proximal region epitopes: antibody binding kinetics, induction, and potential for regulation in acute infection. J Virol 82: 115-125.
41. Altman JD, Moss PA, Goulder DH, Barouch MG, McHeyzer-Williams JI, et al. (1996) Phenotypic analysis of antigen-specific T lymphocytes. Science 274: 94-96.
42. Tian Y, Ramesh CV, Ma X, Naqvi S, Patel T, et al. (2002) Structure-affinity relationships in the gp41 ELDKWA epitope for the HIV-1 neutralizing monoclonal antibody 2F5: effects of side-chain and nackbone modifications and conformational constraints. J Pept Res 59: 264-276.
43. Parker CE, Deterding LJ, Hager-Braun C, Binley JM, Schulke N, et al. (2001) Fine definition of the gp41 epitope of the gp41 glycoprotein of human immunodeficiency virus type 1 for the neutralizing monoclonal 2F5. J Virol 75: 10906-10911.
44. Ueda Y, Liao D, Yang K, Patel A, Kelsoe G (2007) T-independent activation-induced cytidine deaminase expression, class-switch recombination, and antibody production by immature/transitional 1 B cells. J Immunol 178: 3593-3601.
45. Martin F, Kearney JF (2000) B-cell subsets and the mature preimmune repertoire. Marginal zone and B1 B cells as part of a "natural immune memory". Immunol Rev 175: 70-79.
46. Martin F, Kearney JF (2001) B1 cells: similarities and differences with other B cell subsets. Curr Opin Immunol 13: 195-201.
47. Newman J, Rice JS, Wang C, Harris SL, Diamond B (2003) Identification of an antigen-specific B cell population. J Immunol Methods 272: 177-187.
48. Rice JS, Newman J, Wang C, Michael DJ, Diamond B (2005) Receptor editing in peripheral B cell tolerance. Proc Natl Acad Sci U S A 102: 1608-1613.
49. Zolla-Pazner (2005) Improving on nature: focusing the immune response on the V3 loop. Hum Antibodies 14: 69-72.
50. Montero M, van Houten NE, Wang X, Scott JK (2008) The membrane proximal external region of the human immunodeficiency virus type 1 envelope: dominant site of antibody neutralization and target for vaccine design. Microbiol Mol Biol Rev 72: 54-58.
51. Martin F, Kearney JF (2002) Marginal Zone B cells. Nature Immunol. Rev 2: 323-335.
52. Goodyear CS, Silverman GJ (2005) B cell superantigens: a microbe's answer to innate-like B cells and natural antibodies. Springer Semin Immunopathol 26: 463-484.
53. Berberian L, Shukla J, Jefferis R, Braun J (1994) Effects of HIV infection on VH3 (D12 idiotope) B cells in vivo. J Acquir Immune Defic Syndr 7: 641-646.
54. Karray S, Juompan L, Maroun RC, Isenberg D, Silverman GJ, et al. (1998) Structural basis of the gp120 superantigen-binding site on human immunoglobulins. J Immunol 161: 6681-6688.
55. Karray S, Zouali M (1997) Identification of the B cell superantigen-binding site of HIV-1 gp120. Proc Natl Acad Sci U S A 94: 1356-1360.
56. Neshat MN, Goodglick L, Lim K, Braun J (2000) Mapping the B cell superantigen binding site for HIV-1 gp120 on a V(H)3 Ig. Int Immunol 12: 305-312.
57. Muller S, Kohler H (1997) B cell superantigens in HIV-1 infection. Int Rev Immunol 14: 339-349.
58. Chang Q, Abadi J, Rosenberg M, Pirofski LA (2004) VH3 gene expression in children with HIV infection. J Infect 49: 274-282.
59. Muller S, Wang H, Silverman GJ, Bramlet G, Haigwood N, et al. (1993) B-cell abnormalities in AIDS: stable and clonally-restricted antibody response in HIV-1 infection. Scand J Immunol 38: 327-334.
60. Scamurra RW, Miller DJ, Dahl L, Abrahamsen M, Kapur V, et al. (2000) Impact of HIV-1 infection on VH3 gene repertoire of naive human B cells. J Immunol 164: 5482-5491.
61. Forsgren A, Sjoquist J (1966) Protein A from S.aureus. I. Pseudoimmune reaction with human gamma globulin. JImmunol 97: 822-831.
62. Roben P, Salem A, Silverman GP (1995) VH3 antibodies bind domain D of staphyloccocal protein A. JImmunol 154: 6437-6446.
63. Morahan G, Berek C, Miller J (1983) An idiotypic determinant formed by both immunoglobulin constant and variable regions. Nature 301: 720-722.
64. Silverman GP, Cary SP, Dwyer DC, Luo L, Wagenknecht R, et al. (1998) A B cell superantigen-induced persistent "Hole" in the B-1 repertoire. J Exp Med 192: 87-98.
65. Pennell CA, Sheehan KM, Brodeur PH, Clarke SH (1989) Organization and expression of VH gene families preferentially expressed by Ly-1+ (CD5) B B cells. Eur J immunol 19: 2115-2121.
66. Blomberg B, Geckeler WR, Weigert M (1972) Genetics of the antibody response to dextran in mice. Science 177: 178-80.
67. Acha-Orbea H, McDonald HR (1995) Superantigens of mouse mammary tumor virus. Annual Rev Immunol 13: 459-486.
68. Kouskoff V, Famiglietti S, Lacaud G, Lang P, Rider JE, et al. (1998) Antigens varying in affinity for the B cell Receptor induce differential B lymphocyte responses. J Exp Med 188: 1453-1464.
69. Bikoff EK (1991) Class II-restricted IgG2ab-specific T cells recognize a signal-minus form of the V-CH3b antigen. JImmunol 21: 1411-1423.
70. Bikoff EK, Birshtein BK (1986) T cell clones specific for IgG2a of the a allotype:direct evidence for presentation of endogenous antigen. J Immunol 137: 28-41.
71. Cariappa A, Tang M, Parng C, Nebeltskiy E, Carroll M, et al. (2001) The follicular versus marginal zone B lymphocyte fate decision is regulated by Aiolos, Btk, and CD21. Immunity 14: 603-615.
72. Loder F, Mutschler B, Ray RJ, Paige CJ, Sideras P, et al. (1999) B cell devlopment in the spleen takes place in discrete steps and is determined by the quality of B cell receptor-derived signals. J Exp Med 190: 75-89.
73. Martin F, Kearney JF (2000) Positive selection from newly formed to marginal zone B cells depends on the rate of clonal production, CD19, and Btk. Immunity 12: 39-49.
74. Allman D, Lindsley RC, DeMuth W, Rudd K, Shinton SA, et al. (2001) Resolution of three nonproliferative immature splenic B cell subsets reveals multiple selection points during peripheral B cell maturation. J Immunol 167: 6834-6840.
75. Gorelik L, Cutler AH, Thill G, Miklasz SD, Shea DE, et al. (2004) Cutting edge: BAFF regulates CD21/35 and CD23 expression independent of its B cell survival function. J Immunol 172: 762-766.
76. Hayakawa K, Ishii R, Yamasaki K, Kishimoto T, Hardy RR (1987) Isolation of high-affinity memory B cells: phycoerythrin as a probe for antigen-binding cells. Proc Natl Acad Sci U S A 84: 1379-1383.
77. Liao H-X, Sutherland LL, Xia S-M, Brock ME, Scearce RM, et al. (2006) A group M consensus envelope glycoprotein induces antibodies that neutralize subsets of subtype B and C HIV-1 primary viruses. Virology 353: 268-282.
78. Wyatt R, Moore J, Accola M, Desjardin E, Robinson J, et al. (1995) Involvement of the V1/V2 variable loop structure in the exposure of human immunodeficiency virus type 1 gp120 envelopes by receptor binding. J Virol 69: 5723-5733.
79. Korber B, Gaschen B, Yusim K, Thakallapally R, Kesmir C, et al. (1998) Numbering Positions in HIV Relative to HXB2CG. In: Human Retroviruses and AIDS, Korber B, Kuiken CL, Foley BT, Hahn BH, McCutchan F, Mellors JW, Sodroski J, eds. pp 102-111.
80. Haynes BF, Ma B, Montefiori DC, Wrin T, Petropoulos CJ, et al. (2006) Analysis of HIV-1 subtype B third variable region peptide motifs for induction of neutralizing antibodies against HIV-1 primary isolates. Virology 345: 44-55.
81. Gaynor B, Putterman C, Valadon P, Spatz L, Scharff MD, et al. (1997) Peptide inhibition of glomerular deposition of an anti-DNA antibody. Proc Natl Acad Sci U S A 94: 1555-1960.